JP2005082523A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005082523A5 JP2005082523A5 JP2003315087A JP2003315087A JP2005082523A5 JP 2005082523 A5 JP2005082523 A5 JP 2005082523A5 JP 2003315087 A JP2003315087 A JP 2003315087A JP 2003315087 A JP2003315087 A JP 2003315087A JP 2005082523 A5 JP2005082523 A5 JP 2005082523A5
- Authority
- JP
- Japan
- Prior art keywords
- homocysteic acid
- homocysteine
- disease
- metabolism
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VBOQYPQEPHKASR-VKHMYHEASA-N Homocysteic acid Chemical compound OC(=O)[C@@H](N)CCS(O)(=O)=O VBOQYPQEPHKASR-VKHMYHEASA-N 0.000 claims description 44
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims description 23
- 230000036740 Metabolism Effects 0.000 claims description 13
- 230000004060 metabolic process Effects 0.000 claims description 13
- 230000035786 metabolism Effects 0.000 claims description 13
- 206010053643 Neurodegenerative disease Diseases 0.000 claims description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 229940088597 Hormone Drugs 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- 239000005556 hormone Substances 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 6
- 230000002503 metabolic Effects 0.000 claims description 6
- 229940107161 Cholesterol Drugs 0.000 claims description 5
- MMXZSJMASHPLLR-UHFFFAOYSA-N Pyrroloquinoline quinone Chemical compound C12=C(C(O)=O)C=C(C(O)=O)N=C2C(=O)C(=O)C2=C1NC(C(=O)O)=C2 MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 claims description 5
- 239000000935 antidepressant agent Substances 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 230000002194 synthesizing Effects 0.000 claims description 5
- 230000001430 anti-depressive Effects 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 18
- 206010061536 Parkinson's disease Diseases 0.000 description 11
- 206010001897 Alzheimer's disease Diseases 0.000 description 9
- 230000003834 intracellular Effects 0.000 description 9
- 102000003802 alpha-Synuclein Human genes 0.000 description 8
- 108090000185 alpha-Synuclein Proteins 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 210000004027 cells Anatomy 0.000 description 7
- BUGYDGFZZOZRHP-UHFFFAOYSA-N Memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229960004640 memantine Drugs 0.000 description 6
- 210000002569 neurons Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000001629 suppression Effects 0.000 description 4
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 3
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 231100000676 disease causative agent Toxicity 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- DZHSAHHDTRWUTF-SIQRNXPUSA-N β-amyloid polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 3
- 210000001175 Cerebrospinal Fluid Anatomy 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 230000003042 antagnostic Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000001537 neural Effects 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 229960005486 vaccines Drugs 0.000 description 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 210000003722 Extracellular Fluid Anatomy 0.000 description 1
- 229960000304 Folic Acid Drugs 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 108009000578 Oxidative Stress Proteins 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229940011671 Vitamin B6 Drugs 0.000 description 1
- 229930003629 Vitamin B6 Natural products 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 125000003346 cobalamin group Chemical group 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003540 gamma secretase inhibitor Substances 0.000 description 1
- 230000004065 mitochondrial dysfunctions Effects 0.000 description 1
- 210000003867 nerve cell Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 230000001737 promoting Effects 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 230000001502 supplementation Effects 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 150000003697 vitamin B6 derivatives Chemical class 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003315087A JP2005082523A (ja) | 2003-09-08 | 2003-09-08 | 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003315087A JP2005082523A (ja) | 2003-09-08 | 2003-09-08 | 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005082523A JP2005082523A (ja) | 2005-03-31 |
| JP2005082523A5 true JP2005082523A5 (fr) | 2006-11-09 |
Family
ID=34415455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003315087A Pending JP2005082523A (ja) | 2003-09-08 | 2003-09-08 | 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2005082523A (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007230912A (ja) * | 2006-03-01 | 2007-09-13 | Mitsubishi Gas Chem Co Inc | 神経再生促進剤、および該促進剤を含む機能性食品 |
| JP2007269769A (ja) * | 2006-03-10 | 2007-10-18 | Ultizyme International Ltd | 神経変性疾患関連蛋白質凝集線維化抑制剤 |
| WO2007116458A1 (fr) * | 2006-03-30 | 2007-10-18 | Tohru Hasegawa | Agent thérapeutique pour maladie neurodégénérative |
| EP2011498A4 (fr) * | 2006-04-10 | 2009-11-11 | Mitsubishi Gas Chemical Co | Agent ameliorant les fonctions cerebrales et aliment fonctionnel contenant l'agent ameliorant |
| WO2009078445A1 (fr) * | 2007-12-17 | 2009-06-25 | Alfresa Pharma Corporation | Préparation pharmaceutique |
| JP2012158527A (ja) * | 2011-01-31 | 2012-08-23 | Mitsubishi Gas Chemical Co Inc | うつ予防 |
| WO2015060317A1 (fr) * | 2013-10-22 | 2015-04-30 | 長谷川亨 | Procédé de dépistage de maladie neurodégénérative |
| JP2017175966A (ja) * | 2016-03-29 | 2017-10-05 | 三菱瓦斯化学株式会社 | ピロロキノリンキノン含有紅茶風飲料 |
| JP7332489B2 (ja) * | 2019-01-28 | 2023-08-23 | サントリーホールディングス株式会社 | ホスホジエステラーゼ３阻害用組成物及び血小板凝集抑制用組成物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02196720A (ja) * | 1989-01-12 | 1990-08-03 | Fuji Kagaku Kogyo Kk | 脳疾患用剤 |
| JPH06211660A (ja) * | 1992-02-07 | 1994-08-02 | Sagami Chem Res Center | 神経成長因子産生促進剤 |
| GB9916536D0 (en) * | 1999-07-14 | 1999-09-15 | Scarista Limited | Nutritional or pharmaceutical compositions |
| WO2001049307A1 (fr) * | 1999-12-30 | 2001-07-12 | Proteotech, Inc. | Catechines et extrait de the vert destines au traitement de l'amyloidose dans la maladie d'alzheimer et d'autres amyloidoses |
| JP2004231585A (ja) * | 2002-12-05 | 2004-08-19 | Fancl Corp | 生体内ホモシステインレベル低減用および上昇抑制用組成物 |
-
2003
- 2003-09-08 JP JP2003315087A patent/JP2005082523A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220071929A1 (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| Bush | Copper, zinc, and the metallobiology of Alzheimer disease | |
| EP2367529A1 (fr) | Composition destinées à être utilisées pour le traitement de la maladie d'alzheimer | |
| ES2462553A1 (es) | Composición para mejora del bienestar sexual | |
| JP2019518034A (ja) | 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用 | |
| JP2005082523A5 (fr) | ||
| JP2005082523A (ja) | 神経変性疾患特にアルツハイマー病及びパーキンソン病の根本治療薬 | |
| Musa et al. | Preventive activity of ascorbic acid on lead acetate induced cerebellar damaged in adult wistar rats | |
| EP3461479A1 (fr) | Compositions nutraceutiques et pharmaceutiques et leurs utilisations pour conserver les fonctions cognitives | |
| US20200093929A1 (en) | Pharmaceutical composition for the prevention and treatment of memory and cognitive deficits related to ageing | |
| Pinton et al. | p, p′-Methoxyl-diphenyl diselenide prevents neurodegeneration and glial cell activation induced by streptozotocin in rats | |
| JP2003535134A (ja) | 痴呆治療剤 | |
| US20050019423A1 (en) | Method for treating amyotrophic lateral sclerosis | |
| Muss et al. | Neuroprotective impact of a vitamin trace element composition-a randomized, double blind, placebo controlled clinical trial with healthy volunteers | |
| US11612583B2 (en) | Disease modifying methods for treating neurodegenerative diseases using nootropic agents | |
| US11116246B2 (en) | Compositions of coenzyme Q10 and methods of use | |
| Kuznetsova et al. | The influence of different aluminium compounds on the hippocampal morphofunctional state and conditioning in mice | |
| AR080292A1 (es) | Metodo para normalizar en forma rapida los niveles de vitamina b12 en un paciente que tiene deficiencia de vitamina b12 y un nivel promedio de vitamina b12 por debajo de 350 pg/ml | |
| US20160213644A1 (en) | Regulation of Body Weight Gain By Using Dibenzo-Alpha-Pyrones | |
| TW200626133A (en) | Oral medication for twice-daily administration | |
| Stephens et al. | Aluminum and Alzheimer’s disease | |
| US9192641B2 (en) | Health supplement using guarana extract | |
| Abdul-Rasoul et al. | Effect of aluminium chloride on sexual efficiency in adult male rats | |
| Tanideh et al. | Effects of Pentoxifylline in a Rat Model of Manganism: Evaluation of the Possible Toxicity | |
| JP4896531B2 (ja) | 血中ＣｏＱ１０量を増加させる医薬組成物 |